L-Hist Mont Junior Tablet DT is a combination medication containing Levocetirizine 2.5 mg and Montelukast 4 mg, formulated for pediatric use to manage allergic conditions. Levocetirizine is a potent, second-generation antihistamine that selectively inhibits peripheral H1 receptors, effectively reducing symptoms such as sneezing, rhinorrhea, nasal itching, and urticaria by blocking histamine action. Montelukast, a leukotriene receptor antagonist, prevents leukotriene-mediated bronchoconstriction, inflammation, and mucus production, thereby improving respiratory function in conditions such as allergic rhinitis and asthma. This dual-action tablet provides comprehensive relief from allergic symptoms by targeting both histamine and leukotriene pathways. The dispersible tablet formulation allows for easy administration in children who may have difficulty swallowing conventional tablets. L-Hist Mont Junior Tablet DT is indicated for the treatment of allergic rhinitis, chronic urticaria, and as adjunctive therapy in asthma management in pediatric patients. It is generally well-tolerated, with a favorable safety profile; however, adverse effects such as headache, somnolence, or gastrointestinal discomfort may occur. Use should be guided by a healthcare professional, considering individual patient needs and contraindications. This combination therapy offers an effective approach to controlling pediatric allergic symptoms, enhancing patient compliance and quality of life.